Short Interest in Clearmind Medicine Inc. (NASDAQ:CMND) Drops By 48.9%

Clearmind Medicine Inc. (NASDAQ:CMND) saw a significant decrease in short interest in the month of August. As of August 31st, there was short interest totaling 25,174 shares, a decrease of 48.9% from the August 15th total of 49,268 shares. Currently, 2.5% of the shares of the stock are short sold. Based on an average trading volume of 188,915 shares, the short-interest ratio is currently 0.1 days.

Clearmind Medicine Price Performance

Shares of NASDAQ:CMND traded down $0.08 during midday trading on Tuesday, hitting $0.86. The company had a trading volume of 167,080 shares, compared to its average volume of 1,013,370. Clearmind Medicine has a twelve month low of $0.83 and a twelve month high of $524.00. The stock has a market cap of $880,721.70, a price-to-earnings ratio of -0.02 and a beta of 0.81. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.31 and a quick ratio of 4.31. The business’s 50-day simple moving average is $1.68 and its 200-day simple moving average is $4.78.

Clearmind Medicine (NASDAQ:CMND) last posted its earnings results on Thursday, September 10th. The company reported ($0.57) earnings per share for the quarter.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of Clearmind Medicine from a “strong sell” rating to a “sell” rating in a report on Saturday, June 20th.

Clearmind Medicine Company Profile

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.